Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms
Seug Yun Yoon, Sung-Yong Kim
Korean J Intern Med. 2023;38(6):810-817. Published online 2023 Nov 1 DOI: https://doi.org/10.3904/kjim.2023.333
Citations to this article as recorded by 
Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study
Seug Yun Yoon, Sung‐Soo Yoon, Deok‐Hwan Yang, Gyeong‐Won Lee, Sang Kyun Sohn, Ho‐Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun‐Ji Choi, June‐Won Cheong, Soo‐Mee Bang, Joon Seong Park, Suk Joong Oh, Yong Park, Young Hoon Park, Sung‐Eun Lee
International Journal of Cancer.2025; 157(3): 526. CrossRef
Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study
Seug Yun Yoon, Sung-Eun Lee
Blood Research.2024;[Epub] CrossRef
Therapeutic potential of anticancer activity of nitrogen-containing heterocyclic scaffolds as Janus kinase (JAK) inhibitor: Biological activity, selectivity, and structure–activity relationship
Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Moumita Saha, Rajiv Patel
Bioorganic Chemistry.2024; 152: 107696. CrossRef